- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06246903
INTER-PATHOLOGIST READER STUDY
January 30, 2024 updated by: Orlucent, Inc
This is a post study histology analysis from previously obtained pathology slides.
Study Overview
Status
Enrolling by invitation
Conditions
Detailed Description
This is a post study histology analysis.
Pathologists will use digital histology slide scans of suspicious nevus/nevi obtained from previously conducted studies to provide histopathology gradations of histological features as outlined in the Orlucent histology atlas (LBL0713 Histopathology Atlas for Grading of Dysplastic Nevi and DEF0713-1 Histopathology Definitions for LBL0713).
Study Type
Observational
Enrollment (Estimated)
500
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Utah
-
Salt Lake City, Utah, United States, 84132
- University of Utah Hospital, Pathology
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Previous consented subject's scans from the Orlucent OMS002, SFI001 or SFI003 Studies and
Description
Inclusion Criteria:
- Histology scans must have been obtained from previous consented subjects that allows post study ad hoc analyses.
- Histology scans must be available from the data collected from the Orlucent OMS002, SFI001 or SFI003 Studies and are of good quality.
Exclusion Criteria:
- NA
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
suspicious nevus/nevi
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Study Success
Time Frame: 8 months
|
This is a data collection study.
Study success is considered when the interpathology agreement is improved when compared to the agreement identified in Elmore et al. [5].
[(classes/agreement): class I (eg, nevus or mild atypia) / 92% (95% confidence interval 90% to 94); class II (eg, moderate atypia) / 25% (22% to 28%); III (eg, severe atypia or melanoma in situ) / 40% (37% to 44%); IV (eg, pathologic stage T1a (pT1a) early invasive melanoma) / 43% (39% to 46%); and V (eg, ≥pT1b invasive melanoma) / 72% (69% to 75%).]
|
8 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Cathy Shachaf, PhD, Founder and President
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 15, 2023
Primary Completion (Estimated)
June 20, 2024
Study Completion (Estimated)
August 1, 2024
Study Registration Dates
First Submitted
January 30, 2024
First Submitted That Met QC Criteria
January 30, 2024
First Posted (Estimated)
February 7, 2024
Study Record Updates
Last Update Posted (Estimated)
February 7, 2024
Last Update Submitted That Met QC Criteria
January 30, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SFI006
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Nevi, Dysplastic
-
Nova Scotia Health AuthorityUnknown
-
NYU Langone HealthCompleted
-
University of Illinois at ChicagoWithdrawnDysplastic Nevus SyndromeUnited States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)CompletedMelanoma | Health Status Unknown | Dysplastic Nevus | No Evidence of DiseaseUnited States
-
National Cancer Institute (NCI)Completed
-
Sidney Kimmel Comprehensive Cancer Center at Johns...Johns Hopkins University; National Cancer Institute (NCI)CompletedMelanomaUnited States
-
Russian Academy of Medical SciencesBlokhin's Russian Cancer Research CenterRecruitingMelanoma | Nevus | Nevus, Pigmented | Melanoma (Skin) | Mucosal Melanoma | Moles | Dysplastic Nevus Syndrome | Nevus, Blue | Nevus, Spitz | Nevi, Spindle Cell | Nevi, Dysplastic | Mucosal MelanosisRussian Federation
-
Region SkaneRecruitingMelanoma | Mutation | Image | Dysplastic Nevi | Melanoma in Situ | Mole (Dermatology)Sweden
-
Assuta Hospital SystemsUnknownMelanoma | Pigmented Skin Lesion | Dysplastic NeviIsrael
-
John KirkwoodCompletedMelanoma | Atypical NeviUnited States